
🚨 A new cancer vaccine appears to significantly improve survival in people in remission from acute myeloid leukemia (AML), according to new results from a phase 3 clinical trial. The vaccine, galinpepimut-S (GPS), is an “off-the-shelf” vaccine invented by MSK leukemia specialist and physician-scientist Dr. David A. Scheinberg (@DASLab_MSKCC). In the trial of 126 patients, it reduced the risk of death by 41%. Median overall survival was 24.0 months with the vaccine compared with 14.7 months for patients on standard treatments. “These data bring us closer to having the first off-the-shelf vaccine for AML patients." Learn more: bit.ly/4fDoAmS
























